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ly differentiated adenocarcinoma. Immunostains were positive for
CDX2, CK20, CA125, and CK7 and negative for ER. Based on the clin-
ical picture and immunostains the pelvic tumour was diagnosed as
colonic in origin.
One month after initial imaging, the patient underwent attempted
debulking surgery involving right hemi-colectomy, resection of the ter-
minal ileum and caecum with ileostomy and mucus ﬁstula formation.
The tumour was densely adherent to the right anterior abdominal
wall, mesentery of the small bowel, sigmoid colon, caecum and bladder.
The proximal colon was dilated, indicating partial obstruction second-
ary to tumour, requiring a right hemicolectomy. Tumour was resectedIntroduction
Case
A 60 year-old female was referred to Gynaecology clinic with ab-
dominal distention and a palpable abdominal mass extending above
the umbilicus. She was para two (normal deliveries), and post-
menopausal for 10 years with no subsequent bleeding per vagina. She
followed routine cervical screening smears, had never taken hormone
replacement therapy (HRT), and was a non-smoker. She had no past
medical history or family history of gynaecological or breast malignan-
cy. Tumour markers were taken; CEA = 75.3 μg/L, CA199 = 81 kU/L,
CA125= 194 kU/L, and a CT abdomen and pelvis arranged querying
bowel or ovarian primary given the raised tumour markers. Post-
operative tumour markers included alpha feto-protein (AFP) =
11,677 kU/L and beta human chorionic gonadotrophin (hCG) = 8
mIU/L.
CT scan revealed a large midline mass (23 × 11.5 × 18.5 cm) pre-
dominantly cystic, with poorly deﬁned walls, compressing and indis-
tinguishable from the large bowel near the caecum and sigmoid
colon, with bilateral hydronephrosis and hydroureter. The mass
was deemed likely ovarian (bilateral) in origin with no signiﬁcant
lymphadenopathy, omental or extra-pelvic disease. However, given
the raised CA199, CEA and the radiological appearances of a mass in-
separable from the large bowel, the patient underwent US guidedcs and Gynaecology, Barnsley
outh Yorkshire S75 2EP, UK.
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.from the small bowel and the right anterior abdominal wall and blad-
der, being removed in piecemeal fragments.
Intra-operatively, superﬁcial and deep hepatic nodules were palpa-
ble hence maximal debulking was not deemed appropriate given the
extent of disease spread. The uterus, right or left ovary could not be sep-
arately identiﬁed from the tumour bulk, and the pelvis was inaccessible
due to the large mass (20 cm size). Therefore the procedure was com-
pleted and further extra-colonic resection was not performed.Pathology
The pelvic tumour was extensively sampled and morphology
showed a necrotic, heterogeneous tumourwith solid, reticular and glan-
dular pattern. Therewere goblet cells present in keepingwith intestina
differentiation. The tumour showed Schiller Duval bodies, on the basis
of which an AFP immunostain was performed, which was strongly
and diffusely positive (Fig. 1). This conﬁrmed the diagnosis of a yolk
sac tumour. The tumour was positive for AE1/3, focally for CA125
CDX2, beta hCG, and very focally positive for CK7 and CK20. The tumour
was negative for p53,WT1, CD10 and CD56. Therewas no endometrioid
or serous carcinoma component present in the tumour. Compressed
ovarian stroma was identiﬁed thereby conﬁrming an ovarian origin
(Fig. 2).
The right hemi-colectomy specimen showed tumour cells with a
similar morphology to the pelvic tumour, which inﬁltrated into the
mesenteric fat, mucosa of the ileum, base of the appendix and caecum
The overlying mucosa was intact. Lymph nodes showed no evidence
of tumour metastases.
Based onmorphology and immunohistochemistry, the ﬁnal diagno-
sis was classiﬁed as primary ovarian yolk sac tumour (malignant germ
cell tumour) with focal intestinal differentiation.
Fig. 1. Yolk sac tumour 40×: AFP immunostain stain positive.
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Post-surgical CT imaging 17 days post-operatively revealed pelvic
recurrence, peritoneal thickening, liver metastases and small bowel ob-
struction. The disease was deemed rapidly progressive. A long line was
inserted and total parental nutrition (TPN) commenced. Due to the
presence of hepatic metastases, the patient was initially commenced
on 2 cycles of EP chemotherapy (etoposide and cisplatin) before
switching to POMB–ACE (POMB: methotrexate, vincristine, cisplatin,
bleomycin; ACE: acinomycin, cyclophosphamide, etoposide) used
for high risk germ cell tumours. EP induction allows chemotherapy
to be delivered to patients who would otherwise develop major tox-
icity if they received full dose POMB ﬁrst line. Following EP therapy,
the patient had a marked clinical response and a dramatic reduction
in AFP and beta hCG tumour markers. She remains under Oncology
follow-up.Discussion
Ovarian germ cell tumours (OGCT) are rare, accounting for 2–5% of
ovarian malignancies with an annual incidence of 1:100,000 andFig. 2.Yolk sac tumour, 12.5×:Haematoxylin and eosin stain showing compressed ovarian
stroma.typically occur in young women (median age 19 years) (Bailey and
Church, 2005). Yolk sac (endodermal sinus) tumours are highly malig-
nant non-dysgerminomas and the second commonest (20–25%) sub-
type of ovarian germ cell tumours (Bailey and Church, 2005;
Kammerer-Doak et al., 1996). They characteristically presentwith a rap-
idly enlarging abdominal mass causing abdominal distention and pain,
with raised AFP levels produced by the yolk sac cells. OGCTs are highly
sensitive to combination chemotherapy, yetwere historically associated
with a poor prognosis and can prove fatal without prompt treatment.
Most are unilateral and have subclinical metastases at presentation,
with the tumour spreading locally throughout the peritoneum in pref-
erence to haematogenously. Survival rates of stages I–II yolk sac tu-
mours are 60–100%, falling to 50–75% with stages II–IV disease. 40%
yolk sac tumours displaymixed histologywith dysgerminoma subtypes
(eg: teratoma) (Bailey and Church, 2005).
Germ cell tumours in post-menopausal patients are extremely rare,
with very few case reports in the literature (Kammerer-Doak et al.,
1996; Rutgers et al., 1987; Nogales et al., 1996; Horiuchi et al., 1998;
Mazur et al., 1988; Arai et al., 1999; Brown and Green, 1976; Kinoshita,
1990; Ferracini et al., 1979; Lopez et al., 2003; Oh et al., 2001; Pliskow,
1993; Lange et al., 2012; Filiz et al., 2003; Roma and Przybycin, 2014;
Meguro and Yasuda, 2013), thereby explaining the initial diagnostic un-
certainty in this case report regarding tumour type. Primary debulking
surgerymay not have been performed if pre-operative histology had re-
vealed yolk sac characteristics.
To our knowledge, there are 20 published reports of ovarian en-
dodermal yolk sac tumours in post-menopausal patients ranging be-
tween 53 and 86 years at presentation (Table 1) (Kammerer-Doak
et al., 1996; Rutgers et al., 1987; Nogales et al., 1996; Horiuchi
et al., 1998; Mazur et al., 1988; Arai et al., 1999; Brown and Green,
1976; Kinoshita, 1990; Ferracini et al., 1979; Lopez et al., 2003; Oh
et al., 2001; Pliskow, 1993; Lange et al., 2012; Filiz et al., 2003;
Roma and Przybycin, 2014; Meguro and Yasuda, 2013). Most (Oh
et al., 2001) cases involved mixed yolk sac tumours with embryonal,
endometrioid carcinoma, cystadenoma/cystadenoﬁbroma or
cystadenocarcinoma subtypes, the oldest case being 82 years of age
(Kammerer-Doak et al., 1996; Rutgers et al., 1987; Nogales et al.,
1996; Horiuchi et al., 1998; Mazur et al., 1988; Arai et al., 1999;
Lopez et al., 2003; Roma and Przybycin, 2014; Meguro and Yasuda,
2013). The remainder involved pure yolk sac tumour histology
with the oldest reported patient being 86 years of age (Brown and
Green, 1976; Kinoshita, 1990; Ferracini et al., 1979; Oh et al., 2001;
Pliskow, 1993; Lange et al., 2012; Filiz et al., 2003; Roma and
Przybycin, 2014). There is little knowledge concerning the develop-
ment, treatment and outcome of post-menopausal yolk sac tumours.
It is postulated that their pathogenesis differs from that in young
adults, arising from a transformation or neometaplasia/retro-
differentiation process from surface epithelial cells rather than
from yolk cells alone (Lopez et al., 2003; Lange et al., 2012; Roma
and Przybycin, 2014). This theory is supported by isolated reports
of these tumours originating from endometriotic deposits or
endometrioid carcinomas (Kammerer-Doak et al., 1996; Rutgers
et al., 1987; Nogales et al., 1996; Horiuchi et al., 1998).
Endodermal yolk sac tumours are indeed rare in post-menopausal
patients, but a rapidly enlarging pelvic–abdominal mass accompanied
by raised AFP levels should alert clinicians and prompt appropriate
management.Conﬂict of interest statement
None.Ethics approval
Patient consent obtained.
Table 1
Summary of published case reports (1976–2012) regarding endometrial yolk sac tumours, including age at presentation, pathology and treatment.
Number Paper Age at
presentation
(years)
Histology Endometriosis Treatment Chemotherapy Outcome
1 Kammerer-Doak
D et al. 1996
53 Mixed: EST + embryonal carcinoma No TAH,BSO, omentectomy, appendicectomy,
pelvic and para-aortic lymph node sampling
BEP — bleomycin, etoposide, cisplatin
(3 cycles)
Disease free at 5 years
2 Rutgers et al.
1986
50 Mixed: EST + endometrioid carcinoma Yes TAH,BSO, omentectomy, peritoneal
washings
5 cycles Vincristine/dactinomycin/
cyclophosphamide pre-operatively and
cisplatin/vinblastine post operatively
Deceased from disease
(DOD)
3 Nogales et al.
1996
64 Mixed: EST + endometrioid carcinoma No TAH,BSO Vincristine/dactinomycin/
cyclophosphamide (3 cycles)
Recurrence at 8 months,
deceased at 14 months
4 Nogales et al.
1996
71 Mixed: EST + endometrioid carcinoma Yes TAH,BSO Cisplatin based (6 cycles) Disease free at 12 months
5 Nogales et al.
1996
71 Mixed: EST + endometrioid carcinoma No TAH,BSO Cisplatin based (1 cycle) DOD at 3 months
6 Nogales et al.
1996
73 Mixed: EST + carcinosarcoma No LSO, omentum, appendix and uterine biopsy None DOD at 5 months
7 Horiuchi et al.
1998
53 Mixed: EST + endometrioid carcinomal No TAH,BSO, omentectomy, pelvic lymph node
biopsy
Vinblastine/pepleomycin/cisplatin/
actinomycin D/cyclophosphamide (6 cycles)
DOD at 6 months
8 Aria et al. 1999 71 Mixed: mucinous cystadenocarcinoma-YST No TAH,BSO Cisplatin and etoposide DOD at 6 months
9 Mazur et al. 1988 82 Mixed: mucinous cystadenoﬁbroma-YST No TAH,BSO, omentectomy None Disease free at 2 years
10 Lopez et al. 2003 51 Mixed: EC-YST, mucinous cystadenoma Yes TAH,BSO, omentectomy Cisplatin/etoposide/bleomycin (3 cycles) DOD at 10 months
11 Lange et al. 2012 86 Pure: EST No TAH,BSO, omentectomy, peritoneal stripping BEP — bleomycin, etoposide, cisplatin
(4 cycles)
Not documented
12 Ferracini R et al.
1989
63 Pure: EST No TAH, partial removal of mass. None DOD 2 days post operatively
13 Brown J et al.
1976
57 Pure: EST No TAH,BSO, omentectomy None DOD at 3 months
14 Kinoshita K et al.,
1990
62 Pure: EST No TAH,BSO, omentectomy Cisplatin, vinblastin, peplomycin (5 cycles) Not documented
15 Oh C et al. 2001 75 Pure: EST No TAH,BSO, sigmoid colectomy, omentectomy,
pelvic lymph node biopsy
Etopiside and cisplatin (3 cycles) DOD at 4 months
16 Pliskow S et al.
1993
54 Pure: EST No TAH,BSO, omentectomy Bleomysin, etoposide, cisplatin (3 cycles) Disease free at 2 years
17 Filiz G et al. 2003 76 Pure: EST No TAH, BSO, omentectomy, pelvic and para-
aortic lymph node sampling
Bleomycin, Etoposide and Cisplatin
(4 cycles)
DOD at 6 months
18 Meguro S et al.
2013
58 Mixed: AFP producing adenocarcinoma with
adenoﬁbroma showing germ cell
differentiation
No TAH,BSO, omentectomy Carboplatin and docetaxel (6 cycles) Disease free at 12 months
19 Roma A et al.
2014
61 Mixed: papillary serous high grade
carcinoma with minor components of
endometrioid carcinoma and YST.
No TAH,BSO and staging biopsies Intraperitoneal chemotherapy (6 cycles) Persistent/recurrent disease
at 6 months
20 Roma A et al.
2015
70 Pure: EST Yes TAH,BSO and staging biopsies 6 cycles Recurrence at 7 months
18
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